litlas
ログインアカウント作成

Robert A. Copeland

1988–2025 年に発表

80
論文数
24,623
被引用数
69
h 指数
78
i10 指数

被引用数

Robert A. Copeland の年別被引用数1973 年: 被引用 1 件1984 年: 被引用 1 件1991 年: 被引用 1 件1992 年: 被引用 6 件1993 年: 被引用 6 件1994 年: 被引用 1 件1995 年: 被引用 10 件1996 年: 被引用 22 件1997 年: 被引用 22 件1998 年: 被引用 27 件1999 年: 被引用 60 件2000 年: 被引用 174 件2001 年: 被引用 193 件2002 年: 被引用 211 件2003 年: 被引用 190 件2004 年: 被引用 162 件2005 年: 被引用 143 件2006 年: 被引用 137 件2007 年: 被引用 131 件2008 年: 被引用 118 件2009 年: 被引用 169 件2010 年: 被引用 156 件2011 年: 被引用 222 件2012 年: 被引用 227 件2013 年: 被引用 281 件2014 年: 被引用 332 件2015 年: 被引用 359 件2016 年: 被引用 400 件2017 年: 被引用 463 件2018 年: 被引用 340 件2019 年: 被引用 958 件2020 年: 被引用 846 件2021 年: 被引用 829 件2022 年: 被引用 669 件2023 年: 被引用 460 件2024 年: 被引用 645 件2025 年: 被引用 268 件2026 年: 被引用 23 件1974〜1983 年は被引用が無いため表示していません1985〜1990 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,262 件、この内訳の 32.1%中国: 引用元論文 1,001 件、この内訳の 9.9%イギリス: 引用元論文 858 件、この内訳の 8.5%ドイツ: 引用元論文 610 件、この内訳の 6%カナダ: 引用元論文 422 件、この内訳の 4.2%イタリア: 引用元論文 377 件、この内訳の 3.7%日本: 引用元論文 345 件、この内訳の 3.4%フランス: 引用元論文 321 件、この内訳の 3.2%スイス: 引用元論文 216 件、この内訳の 2.1%オーストラリア: 引用元論文 197 件、この内訳の 1.9%インド: 引用元論文 191 件、この内訳の 1.9%スペイン: 引用元論文 187 件、この内訳の 1.8%
0%32.1%その他 21.3%

機関

分野

  • Biochemistry, Genetics and Molecular Biology55.2%
  • Medicine27.7%
  • Computer Science5.1%
  • Chemistry3.2%
  • Immunology and Microbiology2.5%
  • Neuroscience2.5%
  • その他3.8%

トピック

  • Epigenetics and DNA Methylation6.6%
  • Cancer-related gene regulation4.4%
  • Computational Drug Discovery Methods3.8%
  • Protein Degradation and Inhibitors3.1%
  • RNA modifications and cancer2.6%
  • Histone Deacetylase Inhibitors Research2.4%
  • その他77.1%

共著者

全論文

検索で開く
  1. Drug–target residence time and its implications for lead optimization

    著者: Robert A. Copeland, David L. Pompliano, Thomas D. Meek - Nature Reviews Drug Discovery 2006 被引用: 1,446

  2. The drug–target residence time model: a 10-year retrospective

    著者: Robert A. Copeland - Nature Reviews Drug Discovery 2015 被引用: 733

  3. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

    著者: Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde, Jean‐Marie Michot, Carlo Lucchesi, Andréa Varga, Jean‐Michel Coindre, Stephen J. Blakemore, Alicia Clawson, Benjamin Suttle, Alice McDonald, Mark Woodruff, Scott Ribich, Eric Hedrick, Heike Keilhack, Blythe Thomson, Takashi Owa, Robert A. Copeland, Peter Ho, Vincent Ribrag - The Lancet Oncology 2018 被引用: 614

  4. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

    著者: Sarah K. Knutson, Natalie M. Warholic, Tim J. Wigle, Christine R. Klaus, Christina J. Allain, Alejandra Raimondi, Margaret Porter Scott, Richard Chesworth, Mikel P. Moyer, Robert A. Copeland, Victoria M. Richon, Roy M. Pollock, Kevin W. Kuntz, Heike Keilhack - National Academy of Sciences, Proceedings of the National Academy of Sciences 2013 被引用: 782

  5. Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

    著者: Andrew Fedoriw, Satyajit Rajapurkar, Shane W. O’Brien, Sarah V. Gerhart, Lorna H. Mitchell, Nicholas D. Adams, Nathalie Rioux, Trupti Lingaraj, Scott Ribich, Melissa B. Pappalardi, Niyant Shah, Jenny Laraio, Yan Liu, Michael Butticello, Chris Carpenter, Caretha L. Creasy, Susan Korenchuk, Michael T. McCabe, Charles F. McHugh, Raman P. Nagarajan, Craig D. Wagner, Francesca Zappacosta, Roland S. Annan, N.O. Concha, Roberta Thomas, Timothy K. Hart, J. Joshua Smith, Robert A. Copeland, Mikel P. Moyer, John Campbell, Kim Stickland, James E. Mills, Suzanne Jacques-O’Hagan, Christina J. Allain, Danielle Johnston, Alejandra Raimondi, Margaret Porter Scott, Nigel J. Waters, Kerren K. Swinger, Ann Boriack-Sjodin, Tom Riera, Gideon Shapiro, Richard Chesworth, Rabinder Prinjha, Ryan G. Kruger, Olena Barbash, Helai P. Mohammad - Cancer Cell 2019 被引用: 347

  6. The promise and peril of chemical probes

    著者: C.H. Arrowsmith, James E. Audia, Christopher P. Austin, Jonathan B. Baell, Jonathan P. Bennett, Julian Blagg, C. Bountra, Paul E. Brennan, Peter J. Brown, Mark E. Bunnage, Carolyn Buser‐Doepner, Robert M Campbell, Adrian J. Carter, Philip Cohen, Robert A. Copeland, Ben Cravatt, Jayme L. Dahlin, Dashyant Dhanak, A.M. Edwards, Mathias Frederiksen, Stephen V. Frye, Nathanael S. Gray, Charles E. Grimshaw, David Hepworth, Trevor Howe, K. Huber, Jian Jin, Stefan Knapp, Joanne Kotz, Ryan G. Kruger, Derek Lowe, Mary M. Mader, Brian D. Marsden, Anke Mueller‐Fahrnow, Susanne Müller, Rónán C. O’Hagan, John P. Overington, Dafydd R. Owen, Saul H. Rosenberg, Ruth A. Ross, Bryan L. Roth, Matthieu Schapira, Stuart L. Schreiber, Brian K. Shoichet, M. Sundström, Giulio Superti-Furga, Jack Taunton, Leticia Toledo‐Sherman, Chris Walpole, Michael A. Walters, Timothy M. Willson, Paul Workman, Robert N. Young, William J. Zuercher - Nature Chemical Biology 2015 被引用: 850

  7. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

    著者: Scott R. Daigle, Edward J. Olhava, Carly A. Therkelsen, Aravind Basavapathruni, Lei Jin, P. Ann Boriack‐Sjodin, Christina J. Allain, Christine R. Klaus, Alejandra Raimondi, Margaret Porter Scott, Nigel J. Waters, Richard Chesworth, Mikel P. Moyer, Robert A. Copeland, Victoria M. Richon, Roy M. Pollock - Blood 2013 被引用: 725

  8. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

    著者: Elayne Chan-Penebre, Kristy G. Kuplast, Christina R. Majer, P. Ann Boriack‐Sjodin, Tim J. Wigle, L. Danielle Johnston, Nathalie Rioux, Michael J. Munchhof, Lei Jin, Suzanne L. Jacques, Kip A. West, Trupti Lingaraj, Kimberly Stickland, Scott Ribich, Alejandra Raimondi, Margaret Porter Scott, Nigel J. Waters, Roy M. Pollock, J. Joshua Smith, Olena Barbash, Melissa B. Pappalardi, Thau Ho, Kelvin Nurse, Khyati Oza, Kathleen T. Gallagher, Ryan G. Kruger, Mikel P. Moyer, Robert A. Copeland, Richard Chesworth, Kenneth W. Duncan - Nature Chemical Biology 2015 被引用: 546

  9. Evaluation of Enzyme Inhibitors in Drug Discovery

    著者: Robert A. Copeland - 2013 被引用: 673

  10. Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists.

    著者: Robert A. Copeland - 2005 被引用: 1,061

  11. Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

    著者: Scott R. Daigle, Edward J. Olhava, Carly A. Therkelsen, Christina R. Majer, Christopher J. Sneeringer, Jeffrey Song, L. Danielle Johnston, Margaret Porter Scott, J. Joshua Smith, Yonghong Xiao, Lei Jin, Kevin W. Kuntz, Richard Chesworth, Mikel P. Moyer, Kathrin M. Bernt, Jen‐Chieh Tseng, Andrew L. Kung, Scott A. Armstrong, Robert A. Copeland, Victoria M. Richon, Roy M. Pollock - Cancer Cell 2011 被引用: 934

  12. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

    著者: Christopher J. Sneeringer, Margaret Porter Scott, Kevin W. Kuntz, Sarah K. Knutson, Roy M. Pollock, Victoria M. Richon, Robert A. Copeland - National Academy of Sciences, Proceedings of the National Academy of Sciences 2010 被引用: 680

  13. Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 -Mutant Non-Hodgkin Lymphoma

    著者: Sarah K. Knutson, Satoshi Kawano, Yukinori Minoshima, Natalie M. Warholic, Kuan‐Chun Huang, Yonghong Xiao, Tadashi Kadowaki, Mai Uesugi, Galina Kuznetsov, Namita Kumar, Tim J. Wigle, Christine R. Klaus, Christina J. Allain, Alejandra Raimondi, Nigel J. Waters, J. Joshua Smith, Margaret Porter-Scott, Richard Chesworth, Mikel P. Moyer, Robert A. Copeland, Victoria M. Richon, Toshimitsu Uenaka, Roy M. Pollock, Kevin W. Kuntz, Akira Yokoi, Heike Keilhack - Molecular Cancer Therapeutics 2014 被引用: 522

  14. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

    著者: Sarah K. Knutson, Tim J. Wigle, Natalie M. Warholic, Christopher J. Sneeringer, Christina J. Allain, Christine R. Klaus, Joelle D. Sacks, Alejandra Raimondi, Christina R. Majer, Jeffrey Song, Margaret Porter Scott, Lei Jin, J. Joshua Smith, Edward J. Olhava, Richard Chesworth, Mikel P. Moyer, Victoria M. Richon, Robert A. Copeland, Heike Keilhack, Roy M. Pollock, Kevin W. Kuntz - Nature Chemical Biology 2012 被引用: 761

  15. Antitumor activity of an allosteric inhibitor of centromere-associated protein-E

    著者: Kenneth W. Wood, Latesh Lad, Lusong Luo, Xiangping Qian, Steven D. Knight, Neysa Nevins, Katjuša Brejc, David Sutton, Aidan G. Gilmartin, Penelope Chua, Radhika Desai, Stephen P. Schauer, Dean E. McNulty, Roland S. Annan, Lisa D. Belmont, Carlos Vázquez García, Yan Lee, Melody Diamond, Leo F. Faucette, Michele Giardiniere, ShuYun Zhang, Chiu-Mei Sun, Justin D. Vidal, Serge Lichtsteiner, William D. Cornwell, Joel Greshock, Richard Wooster, Jeffrey T. Finer, Robert A. Copeland, Pearl S. Huang, David J. Morgans, Dashyant Dhanak, Gustave Bergnes, Roman Sakowicz, Jeffrey R. Jackson - National Academy of Sciences, Proceedings of the National Academy of Sciences 2010 被引用: 254

  16. RNA-modifying proteins as anticancer drug targets

    著者: P. Ann Boriack‐Sjodin, Scott Ribich, Robert A. Copeland - Nature Reviews Drug Discovery 2018 被引用: 156

  17. Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma

    著者: Allison E. Drew, Oscar Moradei, Suzanne L. Jacques, Nathalie Rioux, Ann Boriack-Sjodin, Christina J. Allain, Margaret Porter Scott, Lei Jin, Alejandra Raimondi, Jessica L. Handler, Heidi M. Ott, Ryan G. Kruger, Michael T. McCabe, Christopher J. Sneeringer, Thomas V. Riera, Gideon Shapiro, Nigel J. Waters, Lorna H. Mitchell, Kenneth W. Duncan, Mikel P. Moyer, Robert A. Copeland, J. Joshua Smith, Richard Chesworth, Scott Ribich - Scientific Reports 2017 被引用: 136

  18. Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function

    著者: Peter J. Tummino, Robert A. Copeland - Biochemistry 2008 被引用: 546

  19. Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666

    著者: Kenneth W. Duncan, Nathalie Rioux, P. Ann Boriack‐Sjodin, Michael J. Munchhof, Lawrence A. Reiter, Christina R. Majer, Lei Jin, L. Danielle Johnston, Elayne Chan-Penebre, Kristy G. Kuplast, Margaret Porter Scott, Roy M. Pollock, Nigel J. Waters, J. Joshua Smith, Mikel P. Moyer, Robert A. Copeland, Richard Chesworth - ACS Medicinal Chemistry Letters 2015 被引用: 151

  20. Protein methyltransferases as a target class for drug discovery

    著者: Robert A. Copeland, Michael E. Solomon, Victoria M. Richon - Nature Reviews Drug Discovery 2009 被引用: 458

  21. The importance of binding kinetics and drug–target residence time in pharmacology

    著者: Kevin E. Knockenhauer, Robert A. Copeland - British Journal of Pharmacology 2023 被引用: 69

  22. Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase

    著者: Margaret Favata, Kurumi Y. Horiuchi, Elizabeth J. Manos, Andrea J. Daulerio, Deborah A. Stradley, Wendi S. Feeser, Drew E. Van Dyk, William J. Pitts, Richard A. Earl, Frank W. Hobbs, Robert A. Copeland, Ronald L. Magolda, Peggy Scherle, James M. Trzăskos - Journal of Biological Chemistry 1998 被引用: 3,029

  23. The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat

    著者: Kevin W. Kuntz, John E. Campbell, Heike Keilhack, Roy M. Pollock, Sarah K. Knutson, Margaret Porter-Scott, Victoria M. Richon, Chris Sneeringer, Tim J. Wigle, Christina J. Allain, Christina R. Majer, Mikel P. Moyer, Robert A. Copeland, Richard Chesworth - Journal of Medicinal Chemistry 2016 被引用: 171

  24. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor

    著者: Glenn S. Van Aller, Jeff D. Carson, Wei Tang, Hao Peng, Lin Zhao, Robert A. Copeland, Peter J. Tummino, Lusong Luo - Biochemical and Biophysical Research Communications 2011 被引用: 175